From GlobeNewswire: 2025-06-15 11:22:00

In a phase 4 study presented at EAACI, Dupixent was found to be more effective than Xolair in treating chronic rhinosinusitis with nasal polyps in patients with asthma. Results showed Dupixent outperformed Xolair in improving nasal polyp size, sense of smell, lung function, and asthma control within 4 weeks. The study included 360 adults with severe CRSwNP and asthma. The safety profile of Dupixent was similar to Xolair, with no notable differences in adverse events. These findings highlight the efficacy of Dupixent in treating upper and lower respiratory diseases by targeting key inflammation drivers IL-4 and IL-13.

The EVEREST study, a phase 4 randomized trial, demonstrated the superiority of Dupixent over Xolair in treating severe chronic rhinosinusitis with nasal polyps and coexisting asthma. Patients on Dupixent showed significant improvements in nasal polyp size, sense of smell, nasal congestion, and lung function compared to those on Xolair. The study involved 360 adults and showed rapid improvements in symptoms within 4 weeks. Safety outcomes indicated similar rates of adverse events between Dupixent and Xolair, with no major differences in serious adverse events or study discontinuations due to adverse events.



Read more at GlobeNewswire: Press Release: EAACI: Dupixent demonstrated superiority